Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    GOG-0261
Show Display Options
Rank Status Study
1 Active, not recruiting Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
Conditions: Ovarian Carcinosarcoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Sarcoma;   Stage I Ovarian Cancer;   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Cancer;   Stage IA Uterine Sarcoma;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Cancer;   Stage IB Uterine Sarcoma;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Cancer;   Stage IC Uterine Sarcoma;   Stage II Ovarian Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIA Uterine Sarcoma;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIB Uterine Sarcoma;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIA Uterine Sarcoma;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIB Uterine Sarcoma;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IIIC Uterine Sarcoma;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Stage IVA Uterine Sarcoma;   Stage IVB Uterine Sarcoma;   Uterine Carcinosarcoma
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Ifosfamide;   Other: Quality-of-Life Assessment

Indicates status has not been verified in more than two years